RGEN: Repligen Corp. Market Cap to Revenue

Corporate company logo of Repligen Corp. (RGEN)

P/S volatility reflects the market valuation of Repligen Corporation (RGEN), where the current metric stands at 13.20. Stability is underpinned by the duplication of bioprocessing consumables production lines. Monopoly influence over filter pricing guarantees high margins due to the complexity of regulatory reviews. Meanwhile, strategic autonomy is maintained by outsourcing routine production to partners while retaining control over patents.

RGEN repligen.com Price-to-Revenue Ratio (07/04/2022 - 11/13/2026)

Metric breakdowns and analytics for Repligen Corp. (RGEN)

- share price and consensus valuation forecast:
Price Performance Chart repligen.com|RGEN - Analyst Consensus Forecast
- market capitalization information:
Market Valuation Repligen Corp.|RGEN - Total Company Value
- book value of equity indicators:
Net Asset Value per Share Repligen|RGEN - Company Book Value|Market Value to Book Value repligen.com|RGEN - Aggregate Company Assets
- issuer credit burden and liquidity indicators:
Aggregate Debt to Equity Repligen Corporation|RGEN - Long-Term Debt to Equity|Current Liabilities to Capital Repligen Inc.|RGEN - Company Debts|Debt to Net Assets Ratio Repligen Corp.|RGEN - Company Long-Term Debts|Company Short-Term Debts Repligen|Intermediate Liquidity Ratio repligen.com
- earnings and multiples data:
RGEN - Net Profit|Company Profit Forecast Repligen Corporation|RGEN - Price to Earnings Ratio|Projected Price to Earnings Ratio Repligen Corp|RGEN - Price/Earnings to Growth Ratio|Enterprise Value to Operating Income Before Depreciation Repligen Corp.|RGEN - Profit before payment of interest, taxes and amortization|Earnings per share for the trailing year Repligen|RGEN - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year repligen.com|RGEN - Earnings growth in current year|Expected net earnings per share growth next year Repligen Corporation
- total revenue and sales volume data:
RGEN - Company Revenue|Company Revenue Forecast repligen.com|RGEN - P/S Multiple|Market Cap to Projected Revenue Repligen Corp.
Fundamental company analysis:repligen.com, RGEN
Flagship merchandise of Repligen

The P/S ratio reflects the market value of the business per unit of annual revenue, allowing investors to assess the extent of overpayment for assets relative to their ability to generate income. By analyzing changes in the P/S ratio, an investor can observe the market's reaction to financial statements and the intensity of the Repligen Corporation (RGEN) R&D pipeline in bioprocessing and mRNA therapy automation, which determines the fair premium for technological leadership.

Competing companies

TEM (Tempus AI) - Market Capitalization-to-Revenue Ratio|P/S Multiple QGEN (Qiagen)|IONS - Market Cap to Revenue|RNA - Price-to-Revenue Ratio|Price to Sales CRISPR|GeneDx Holdings Corp. (WGS) - Price-to-Revenue Ratio|ultragenyx.com - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Beam Therapeutics|Sarepta Therapeutics - Price-to-Sales Ratio|Price-to-Revenue Ratio Twist Bio (TWST)|TXG - Price to Sales|Price-to-Revenue Ratio Intellia Therapeutics NTLA|Market Capitalization-to-Revenue Ratio STOK|BioLife Solutions - P/S Multiple|WVE - P/S Multiple|MAZE (Maze Tx) - Market Cap to Revenue|SION: Market Cap to Sales Volume|PRME (Prime Medicine, Inc.) - P/S Multiple|tayshagtx.com (TSHA) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio uniQure (QURE)|MGTX - Price to Sales|Price-to-Revenue Ratio Regenxbio RGNX|SLDB: Market Cap to Revenue Ratio|OCGN - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio PACB (pacb.com)|BNTC: P/S Multiple|Price-to-Revenue Multiple Design Therapeutics Inc DSGN|RCKT (Rocket Pharmaceuticals Inc) - P/S Multiple|Price to Sales 4D Molecular Corp FDMT|Price-to-Revenue Ratio Lexeo Therapeutics (LXEO)|korrobio.com - Market Cap to Revenue Ratio|P/S Multiple EDIT (Editas Medicine)|SLN: Market Cap to Revenue Ratio|PRQR - Price-to-Revenue Ratio|CDXS (Codexis, Inc.) - Market Cap to Revenue Ratio|SGMO: P/S Multiple|Nautilus Bio (NAUT) - P/S Multiple|Price-to-Revenue Ratio Metagenomi|DTIL: Market Capitalization-to-Revenue Ratio|P/S Multiple GBIO|BOLD - Price to Sales|Price-to-Revenue Ratio Exicure XCUR|IMNN (Imunon Inc) - Price-to-Sales Ratio|PHIO - Price-to-Revenue Ratio|MBIO: Price-to-Revenue Ratio|RNAZ: P/S Multiple|BNGO - Price-to-Revenue Coefficient|APDN (Applied DNA Sciences) - P/S Multiple|BLUE - Price-to-Revenue Multiple|P/S Multiple IPA|OMGA - Price to Sales|Price-to-Revenue Ratio Singular Genomics Systems Inc OMIC|RGLS: Market Cap to Revenue Ratio|SYRS: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio TBIO (telesisbio.com)|TCON: P/S Multiple|Market Cap to Revenue Unity Biotechnology Inc.